Claimable vs Crosby Health
Two Denials & Appeals vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Claimable | Crosby Health | |
|---|---|---|
| Pricing model | Per-transaction / per-chart · about $40-50 per appeal, some free | Contingency (pay from recoveries) · Managed appeals; SaaS license also offered |
| Speed to go live | consumer self-serve, appeal drafted in minutes | Portal-based upload, light integration |
| Automation model | AI copilot · drafts evidence-backed appeal letters | Autonomous agents · Apollo LLM drafts and submits appeals |
| Built for | Small practices, Enterprise systems | Mid-size groups, Enterprise systems |
| Security posture | SOC 2 Type II, HIPAA | HIPAA |
| Company maturity | 3 yrs (est. 2023) | 4 yrs (est. 2022) |
| Financial backing | $10M · Seed | $2.2M+ · Seed |
| Named customers | None public | 1 named |
| Published results | Specific numbers public | Specific numbers public |
| Documented integrations | None documented | None documented |
| Third-party validation | None found | None found |
Bottom line
- Pick Claimable if patients or one-off denials need fast, cheap, evidence-backed appeals with zero procurement.
- Pick Crosby Health if clinical denials are piling up unworked and you want appeals generated and submitted automatically while paying only from what gets recovered.
Claimable
AI-generated appeals for denied health insurance claims
- Founded
- 2023
- HQ
- Sacramento, CA
- Stage
- Seed
- Raised
- $10M
What it does
- AI-drafted appeals citing policy terms and medical literature
- Delivery to insurer appeals departments and executives
- Coverage for 28 conditions and 90+ treatments
- Support for 80+ medications including Humira and Dupixent
- Case tracking with most resolved within 10 days
Where it's strong
- Reports roughly 75 to 80% of appeals ending in overturned denials, far above typical patient appeal rates.
- Flat per-case pricing around $50 makes it accessible without a contract or implementation.
- Founding team combines clinical, payer, and VA data science backgrounds, and the escalation tactic of copying executives and regulators gets responses.
What buyers should weigh
- Coverage is limited to a defined list of conditions and treatments, so many denial types are out of scope today.
- The core product is patient-facing; provider and enterprise offerings are newer and less proven at volume.
- It appeals one claim at a time and does not address the upstream documentation or authorization issues driving denials.
Crosby Health
AI-generated clinical appeals for denied claims
- Founded
- 2022
- HQ
- New York, NY
- Stage
- Seed
- Raised
- $2.2M+
What it does
- Generates clinical appeal letters for denied claims with AI
- Apollo clinical LLM reads up to 300 pages of documentation
- Finds medical necessity evidence inside clinical notes
- Submits appeals through one unified payer submission channel
- Tracks appeal status and payer decisions with notifications
- Supports medical coding review and chart auditing
Where it's strong
- Attacks a problem most providers simply abandon: appealing every denial, including small balances that are uneconomical to work manually.
- Unified payer submission removes the portal-and-fax maze that makes appeals so labor intensive.
- Early users report appealing denials 300% faster than manual processes.
What buyers should weigh
- Very early company: roughly 15 employees, about $3M raised, and only one publicly named customer.
- Appeals-only focus means it recovers lost revenue but does nothing to prevent denials upstream.
- No publicly documented EHR integrations, so verify how clinical documentation actually gets into the platform.
Named customers
EmpowerMe Wellness
Compare against the rest of Denials & Appeals
Deciding between these two?
First Pass tracks Denials & Appeals every week: funding, launches, and what changed since this page was written.